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PersistentCB1cannabinoidreceptoractivitylimitsneurotransmitterreleaseatvarioussynapsesthroughoutthebrain.However,itisnotfullyunderstood
how constitutively active CB1 receptors, tonic endocannabinoid signaling, and its regulation bymultiple serine hydrolases contribute to the synapse-
specific calibration of neurotransmitter release probability. To address this question at perisomatic and dendritic GABAergic synapses in themouse
hippocampus,weusedacombinationofpairedwhole-cellpatch-clamprecording, liquidchromatography/tandemmassspectrometry,stochasticopti-
cal reconstructionmicroscopy super-resolution imaging, and immunogold electronmicroscopy.Unexpectedly, applicationof theCB1 antagonist and
inverseagonistAM251[N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide],butnottheneutralantag-
onist NESS0327 [8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-5,6-dihydro-4H-benzo[2,3]cyclohepta[2,4-b]pyrazole-3-carboxamine], signifi-
cantly increased synaptic transmission between CB1-positive perisomatic interneurons and CA1 pyramidal neurons. JZL184 (4-nitrophenyl
4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate), a selective inhibitor ofmonoacylglycerol lipase (MGL), the presynap-
tic degrading enzyme of the endocannabinoid 2-arachidonoylglycerol (2-AG), elicited a robust increase in 2-AG levels and concomitantly
decreased GABAergic transmission. In contrast, inhibition of fatty acid amide hydrolase (FAAH) by PF3845 (N-pyridin-3-yl-4-[[3-[5-
(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide) elevated endocannabinoid/endovanilloid anandamide levels but
did not change GABAergic synaptic activity. However, FAAH inhibitors attenuated tonic 2-AG increase and also decreased its synaptic effects.
This antagonistic interaction required the activation of the transient receptor potential vanilloid receptor TRPV1, which was concentrated on
postsynaptic intracellular membrane cisternae at perisomatic GABAergic symmetrical synapses. Interestingly, neither AM251, JZL184, nor
PF3845 affected CB1-positive dendritic interneuron synapses. Together, these findings are consistent with the possibility that constitutively
activeCB1 receptors substantially influenceperisomaticGABAreleaseprobability and indicate that the synaptic effectsof tonic2-AGreleaseare
tightly controlled by presynapticMGL activity and also by postsynaptic endovanilloid signaling and FAAHactivity.
Key words: 2-arachidonoylglycerol; endocannabinod; GABA; hippocampus; interneuron; TRPV1
Significance Statement
Tonic cannabinoid signaling plays a critical role in the regulation of synaptic transmission. However, the mechanistic details of how
persistent CB1 cannabinoid receptor activity inhibits neurotransmitter release have remained elusive. Therefore, electrophysiological
recordings, lipidmeasurements, and super-resolution imagingwere combined to elucidate those signalingmolecules andmechanisms
that underlie tonic cannabinoid signaling. The findings indicate that constitutive CB1 activity has pivotal function in the tonic control of
hippocampalGABArelease.Moreover, theendocannabinoid2-arachidonoylglycerol (2-AG) iscontinuouslygeneratedpostsynaptically,
but its synaptic effect is regulated strictly by presynaptic monoacylglycerol lipase activity. Finally, anandamide signaling antagonizes
tonic 2-AGsignalingvia activationofpostsynaptic transient receptorpotential vanilloidTRPV1receptors. Thisunexpectedmechanistic
diversitymay be necessary to fine-tuneGABA release probability under various physiological and pathophysiological conditions.
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Introduction
Neurons set their synaptic strength by using several signaling
mechanisms that dynamically adjust parameters of synaptic
transmission, including neurotransmitter release probability
(Branco and Staras, 2009). Endocannabinoid signaling is one of
the most widespread and efficient mechanisms to control release
probability via presynaptic CB1 cannabinoid receptor activation
(Lovinger, 2008). Accordingly, CB1 receptors are indispensable
for various phasic forms of synaptic plasticity (Castillo et al.,
2012) and have an essential function in the tonic control of neu-
rotransmitter release (Losonczy et al., 2004; Hentges et al., 2005;
Zhu and Lovinger, 2005; Neu et al., 2007; Oliet et al., 2007).
However, although the molecular mechanisms accounting for
phasic endocannabinoid signaling have been outlined in consid-
erable detail previously (Ohno-Shosaku and Kano, 2014), our
understanding of how tonic regulation of neurotransmitter re-
lease is organized and controlled by specific regulatory mecha-
nisms is rather limited.
The lipid messengers anandamide and 2-arachidonoylglycerol
(2-AG) are both released from postsynaptic neurons and act retro-
gradely on presynaptic CB1 receptors (Ohno-Shosaku and Kano,
2014). Their synaptic levels are determined by complex enzymatic
interactions with numerous synthesis and degradation routes iden-
tified in the brain (Blankman and Cravatt, 2013). Because anand-
amide and 2-AG are known to participate differentially in specific
behavioral processes (Long et al., 2009a), it is generally assumed that
thismolecular and functional complexity reflects divisionof labor in
setting synaptic strength in theunderlyingbraincircuits.However, it
is not clear whether it is 2-AGor anandamide, which primarily con-
tributes to the tonic control of neurotransmitter release at given
circuit locations. For example, previous studies using culture prep-
arations and pharmacological tools with limited target selectivity
arrived at different conclusions concerning the identity of the endo-
cannabinoid responsible for tonic action at hippocampal GABAer-
gic synapses (Hashimotodani et al., 2007; Kim and Alger, 2010).
Moreover, emerging in vitro and in vivo observations raised the pos-
sibility that constitutive receptor activity may also influence axonal
CB1 distribution and tonically attenuate GABA release in the fore-
brain (Leterrier et al., 2006; Meye et al., 2013; Thibault et al., 2013).
Because the cannabinoid tone plays a major role in
interneuron-type-specific and activity-dependent adjustment of
GABAergic synaptic strength, a better understanding of the un-
derlying signaling processes is important (Losonczy et al., 2004;
Ali and Todorova, 2010; Lee et al., 2010). In addition, recent
studies have reported selective, long-term pathological altera-
tions in the tonic endocannabinoid control of GABA release in
rodent models of major brain disorders, including autism, Hun-
tington’s disease, and seizures (Chen et al., 2003, 2007; Dvorzhak
et al., 2013; Fo¨ldy et al., 2013). Therefore, we used paired patch-
clamp recordings in acute brain slices, in combination with mass
spectrometry, stochastic optical reconstruction microscopy
(STORM) super-resolution imaging, and immunogold electron
microscopy, to identify the specific mechanisms that mediate the
tonic control of GABA release in the mouse hippocampus. The
findings indicate that constitutively active CB1 receptors play a
considerable role in the regulation of GABA release probability
and elucidate a functional interaction between intercellular 2-AG
endocannabinoid and intracellular anandamide endovanilloid
signaling in setting the strength of synaptic inhibition.
Materials andMethods
Animals.All protocols related were approved by the Institutional Animal
Care and Use Committee of the University of California, Irvine, and the
Hungarian Committee of the Scientific Ethics of Animal Research
(license number XIV-1-001/2332-4/2012), and all animal experiments
were performed according to the Hungarian Act of Animal Care and
Experimentation (1998, XXVIII, Section 243/1998), which are in accor-
dance with the European Communities Council Directive of November
24, 1986 (86/609/EEC; Section 243/1998). All efforts were made to min-
imize pain and suffering and to reduce the number of animals used.
Adult male C57BL/6 mice aged 4–7 weeks were used in the electrophys-
iological, anatomical, and analytical chemistry experiments. In the elec-
trophysiological experiments testing the role of TRPV1, adult C57BL/6
wild-type and TRPV1/ mice of either sex (The Jackson Laboratory)
aged 4–7 weeks were used.
Electrophysiological recordings. The procedures of electrophysiology
experiments are similar to those described previously by Lee et al. (2010).
Briefly, coronal dorsal hippocampal slices (300 m; anteroposterior,
1.9 to2.8mm frombregma)were prepared fromdeeply anesthetized
mice. After cutting, slices were incubated in sucrose-containing artificial
CSF (ACSF) for 1 h (inmM: 85NaCl, 75 sucrose, 2.5 KCl, 25 glucose, 1.25
NaH2PO4, 4 MgCl2, 0.5 CaCl2, and 24 NaHCO3). All electrophysiologi-
cal recordings weremade at 33°C in ACSF solution (inmM: 126NaCl, 2.5
KCl, 26 NaHCO3, 2 CaCl2, 2 MgCl2, 1.25 NaH2PO4, and 10 glucose).
Slices were visualized with an upright microscope (Olympus BX61WI or
Nikon Eclipse FN1) with infrared differential interference contrast op-
tics. Whole-cell recordings were obtained from the interneurons with
patch pipettes (3–5M) filled with internal solution containing 126mM
K-gluconate, 4mMKCl, 10mMHEPES, 4mMATP-Mg, 0.3mMGTP-Na,
10 mM phosphocreatine, and 0.2% biocytin, pH 7.2, 290 mOsm. The
interneurons were located in the stratum radiatum of the CA1 subfield.
Pyramidal cells (whole-cell voltage-clamp configuration, holding poten-
tial set to70 mV) were recorded with internal solution containing the
following (in mM): 40 CsCl, 90 K-gluconate, 1.8 NaCl, 1.7 MgCl2, 3.5
KCl, 0.05 EGTA, 10 HEPES, 2 MgATP, 0.4 Na2GTP, and 10 mM phos-
phocreatine, pH 7.2 (290 mOsm). In specific experiments, the calcium
chelator BAPTA (10 mM) was also added to the internal solution. All
drugs were obtained from Cayman Chemical, Tocris Bioscience, or
Sigma-Aldrich. Recordings were made using MultiClamp700B amplifi-
ers (MolecularDevices). Signals were filtered at 3 kHz using a Bessel filter
and digitized at 10 or 20 kHz with Digidata 1440A or 1550 analog-to-
digital interfaces (Molecular Devices). Series resistances were carefully
monitored, and recordings were discarded if the series resistance
changed 20% or reached 20 M. The recorded traces were analyzed
using the Clampfit 10 software (Molecular Devices). Action potentials in
presynaptic interneurons were induced in current clamp by injecting 2
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ms square pulses of 1.5–2 nA at 10 Hz frequency. Trains of 50 action
potentials were performed once every minute. Values for the so-called
“effective” unitary IPSC (euIPSC; Neu et al., 2007) amplitudes included
both successful events and failures. To examine drug effects, unless sta-
ted otherwise, brain slices were treated with a drug or amixture (JZL184,
JZL184  AM251, PF3845, PF3845  JZL184, PF3845  JZL184 
AM9810, or AM251  AMG9810, dissolved in the recording ACSF so-
lution) for 40 min before paired recordings were performed (note that
the lipid level measurements were also performed after 40min treatment
of slices with one of the drug conditions or 0.1%DMSOcontrol solution;
for detailed information, see below, Endocannabinoid level measure-
ments by liquid chromatography/tandem mass spectrometry). In spe-
cific experiments, acute drug effects (AM251, NESS0327, JZL184,
JZL184  NESS0327, WIN55,212-2, dissolved in the recording ACSF
solution) were quantified by averaging three series of 50 trials each in the
respective drug conditions. Depolarization-induced suppression of inhi-
bition (DSI) of uIPSCs was produced by using a 0.5-s-long depolarizing
pulse from 70 to 0 mV, and the IPSCs were compared between the
pre-DSI period (2 to 0 s; the latter being the start of the depolarizing
pulse) and the DSI period (0–2 s after the end of the pulse).
Endocannabinoid level measurements by liquid chromatography/tan-
dem mass spectrometry. Acute hippocampal slices were prepared and
treated exactly as hippocampal slices used for electrophysiological exper-
iments. To reduce potential variability in endocannabinoid levels attrib-
utable to the different circuit architecture of dorsal and ventral
hippocampal sections, five 300-m-thick acute hippocampal slices were
pooled in a single measured sample. To exclude potential hemispheric
differences, these slices were collected in an alternate manner from the
left and right hemisphere. Thus, endocannabinoid levels were always
compared between two hippocampal tissue samples derived from an
individual animal, with the tissue being treated by either an enzyme
inhibitor or its corresponding vehicle control. Animals were housed, and
brain slices were prepared in exactly the same manner and at the same
time of the day from one liquid chromatography/tandem mass spec-
trometry (LC/MS/MS) experiment to the next, to further reduce biolog-
ical variability in endocannabinoid levels. After pharmacological
treatment, the hippocampal samples were frozen on dry ice and stored at
70°C until the LC/MS/MSmeasurement. Sample preparation for chro-
matography started with tissue incubation on ice for 30 min in 1 ml of
methanol containing the deuterated internal standards 2-arachidonoyl-
glycerol-d5 (100 ng/ml) and arachidonoyl-ethanolamide-d (1 ng/ml).
After ultrasonic homogenization, samples were centrifuged on an Ep-
pendorf miniSpin microtube centrifuge at 13,400 rpm for 15 min. The
supernatant was transferred into a plastic tube and was diluted with 3 ml
of ultrapure water. The samples were subjected to solid-phase extraction
(SPE) sample clean-up according to the following protocol. First, the SPE
cartridges (SUPELCO Discovery DSC-18 1 ml tubes, 100 mg) were con-
ditioned with 2 ml of methanol and 2 ml of ultrapure water. Diluted
samples were loaded at0.5 ml/min flow rate to apply a gentle vacuum.
In the consecutive washing step, 2 ml of ultrapure water and 2 ml of
methanol/water (50:50 v/v%) were percolated through the sorbent ma-
terial. Elution was performed with 0.7 ml of methanol. Eluates were
diluted to initial HPLC eluent composition with 10 mM ammonium
formate solution.
To measure endocannabinoid levels, we used a PerkinElmer Life and
Analytical Sciences HPLC Series 200 system, which was coupled to an
Applied Biosystems/Sciex 4000QTRAP triple quadrupole/linear ion trap
tandem mass spectrometer operated in positive electrospray ionization
mode. The electronspray ionization ion source parameters were set as
follows: curtain gas, 10; ion spray voltage, 5000 V; temperature, 500°C;
collisionally activated dissociation gas, medium; gas 1, 50; gas 2, 40.
Chromatographic separation was achieved with a Phenomenex Kinetex
C18 column (50mm 3.00mm, 2.6m, 100 Å) usingmethanol and 10
mM ammonium formate as elution solvents at a flow rate of 500 l/min.
The injection volume was 50 l. The initial eluent condition was 80%
methanol/20% buffer that was increased to 85% organic phase during 3
min and then further elevated to 95% during 2 min and was kept at this
condition for 2min. Afterward, the columnwas equilibrated to the initial
condition. Analytes were detected in multiple reaction monitoring
(MRM)mode at the following ion transitions and parameter settings: (1)
2-AG, MRM transition [mass/charge ratio (m/z), 379.4¡ 287.2, 379.4
¡ 91.1], declustering potential (81 V), collision energy (23 V, 81 V), cell
exit potential (10 V, 8 V); (2) 2-arachidonoylglycerol-d5, MRM transi-
tion (m/z, 384.4¡ 287.2, 384.4¡ 91.1), declustering potential (81 V),
collision energy (23 V, 81 V), cell exit potential (10 V, 8 V); (3) arachi-
donoylethanolamide, MRM transition (m/z, 348.4 ¡ 62.1, 348.4 ¡
90.9), declustering potential (51V), collision energy (43V, 63V), cell exit
potential (4 V, 8 V); and (4) arachidonoylethanolamide-d4, MRM tran-
sition (m/z, 352.4¡ 66.0, 352.4¡ 91.2), declustering potential (81 V),
collision energy (41V, 77V), cell exit potential (6V). The peak areaswere
determinedwith Analyst 1.4.2. software. The quantity of the analytes was
calculated by comparing their peak areas with those of the deuterated
internal standards, and it was normalized to the sample weight.
All endocannabinoid standards were purchased from Cayman Chem-
ical. HPLC gradient-grade methanol was supplied by Merck. Ammo-
nium formate was from Riedel-de Hae¨n. Water was purified with a
MilliQ Direct 8 system (Millipore).
Immunostaining for cell-type identification. After in vitro recording
with pipettes containing biocytin, slices were transferred into a fixative
solution containing 4% paraformaldehyde and 0.2% picric acid in 0.1
mM phosphate buffer (PB). Slices were resectioned into 40–70 m thin
sections and tested for CB1 immunopositivity (Fukudome et al., 2004;
CB1-GP-Af530-1; 1:5000, guinea pig; Frontiers Science). A secondary
antibody conjugated to Alexa Fluor 488, raised in donkey against guinea
pig (Invitrogen), were used to detect the location of the primary anti-
body, and streptavidin conjugated to DyLight 594 (1:500; Jackson Im-
munoResearch) was used to visualize biocytin. All primary and
secondary antibodies were diluted in Tris-buffered saline (TBS) contain-
ing 2% normal goat serum. The sections were then mounted in
Vectashield (Vector Laboratories) and analyzed with a fluorescent mi-
croscope (Zeiss Axioscope 2 plus or Nikon Eclipse 80i) at low magnifi-
cation and then with a confocal microscope (Zeiss LSM700 microscope
or Nikon A1R confocal laser-scanning system built on a Ti-E inverted
microscope and operated by NIS-Elements AR software) at high magni-
fication. To evaluate interneuronmorphology, Z-stacks were acquired
throughout the whole axonal arborization of the recorded cells. In
some cases, the biocytin-filled cells were visualized with 3,3-
diaminobenzidine tetrahydrochloride (0.015%) using a standard
ABC kit (Vector Laboratories). Identification of CB1-expressing in-
terneurons was done based on the distinct axonal morphology (peri-
somatic interneurons: axons branching almost exclusively the
pyramidale layer; dendritic interneurons: axons ramifying predomi-
nantly in the stratum radiatum and to a lesser extent in the oriens)
and the immunopositivity for CB1 (Vida et al., 1998; Cope et al., 2002;
Pawelzik et al., 2002; Lee et al., 2010, 2014; Dudok et al., 2015).
Immunostaining for STORM imaging. Immersion-fixed 300-m-thick
acute brain slices containing biocytin-filled cells were developed with
Alexa Fluor 488–streptavidin, covered in Vectashield, and imaged on a
Zeiss LSM780 confocal microscope using a Plan Apochromat 20 ob-
jective (0.8 numerical aperture), and the cell types were evaluated based
on axonalmorphology. After imaging, the slices containing interneurons
selected for STORM imaging were washed and embedded in 2% agarose
in distilledwater, and 20-m-thick coronal sectionswere cut with a Leica
VT-1000S Vibratome in PB and transferred into 24-well tissue culture
plates. Immunostaining was performed in a free-floating manner as de-
scribed previously (Dudok et al., 2015). Briefly, sections were washed in
TBS, blocked with 1% HSA (albumin from human serum; Sigma), and
incubated overnight with an affinity-purified primary antibody (guinea
pig anti-CB1, 1:1000; Fukudome et al., 2004). Sections were then washed
in TBS and incubatedwith a secondary antibody (2g/ml) for 4 h, which
was prepared for STORM imaging by using an unlabeled affinity-
purified anti-guinea pig IgG (Jackson ImmunoResearch), andwas tagged
with Alexa Fluor 647 as reporter and Cy3 as activator. After washing in
TBS and PB, sections were mounted and dried on coverslips. Finally, the
samples were covered with freshly prepared imagingmedium containing
5% glucose, 0.1 M mercaptoethylamine, 1 mg/ml glucose oxidase, and
catalase (2.5l/ml aqueous solution from Sigma;1500U/ml final con-
centration) in Dulbecco’s PBS (Sigma). Coverslips were sealed with nail
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polish and transferred onto the microscope after 10 min incubation in
imaging medium. STORM imaging was performed for up to 3 h after
covering the specimens.
Combined confocal/STORM image acquisition and processing. Corre-
lated STORMand confocal imaging, image processing, and analysis were
performed as described previously (Dudok et al., 2015). Images were
taken using a Nikon Ti-E inverted microscope equipped with CFI Apo
TIRF 100 objective (1.49 numerical aperture), Nikon N-STORM sys-
tem, a Nikon C2 confocal scan head, and an Andor iXon Ultra 897
EMCCD. First, the field of view containing biocytin-labeled axon termi-
nals was selected, and a confocal stack was captured. Next, the astigmatic
3D STORM image of the anti-CB1 immunostaining was acquired, using
1000 cycles of one activator and three reporter frames, 30 ms each. The
low-power activation and the similar imaging depth (5 m) in tissue
for all boutons enabled quantitative evaluation of the number of detected
localization points (LPs), as demonstrated previously (Dudok et al., 2015).
The corresponding deconvolved confocal images and STORM mole-
cule lists were overlaid using custom-writtenmacros inNIH ImageJ. The
outline of the analyzed bouton was determined using the confocal image
of biocytin, and LPs from the STORMdata belonging to the same bouton
were identified. To quantify the internalization of CB1 receptors, the
distance (d) of each CB1 LP was first measured from the 3D center of
mass of all LPs within the given axon terminal. The radius of the terminal
was calculated as the radius of a circle with the same area as the 2D area
measured on the corresponding confocal image of the biocytin-
containing axon terminal. The ratio of internalized receptors was esti-
mated as the ratio of predicted plasma membrane-bound receptors over
total receptors in untreated animals based on previous immunogold
electron microscopy data (88%; Dudok et al., 2015). Subsequently, we
determined the 88%percentile of the d/r values of all individual LPs from
boutons of untreated cells and used this as a threshold to identify inter-
nalized LPs in boutons from control and treated samples. Visualization
of STORM data was achieved by using the N-STORM module in NIS-
Elements AR 4.2 software for 2D images and by using the Visual Molec-
ular Dynamics 1.9.2 software for 3D renderings. The axon terminal
surface was approximated by fitting a 3D convex hull on the LPs. LPs
were visualized as atoms, and convex hull edges were visualized as bonds.
Immunogold staining for electron microscopy. Two wild-type and two
TRPV1/mice (5 weeks old) were anesthetized deeply with ketamine–
xylazine (25 mg/ml ketamine, 5 mg/ml xylazine, and 0.1% w/w pipol-
phen inH2O; 1ml/100 g, i.p.). Animals were perfused transcardially with
0.9% saline for 3 min, followed by 100 ml of 4% paraformaldehyde
fixative in 0.1 M PB, pH 7.4, for 20 min. After perfusion, the brains were
postfixed for 2 h and washed in PB. Hippocampal blocks were sliced into
50-m-thick coronal sections with a Leica VTS-1000 vibratome. After
slicing and extensive washing in 0.1 M PB, the sections were incubated in
10% sucrose for 15 min and 30% sucrose overnight, followed by freeze-
thawing over liquid nitrogen four times. Subsequently, all washing steps
and dilutions of the antibodies were performed in 0.05 M TBS, pH 7.4.
After extensive washing in TBS, the sections were blocked in 1% human
serum albumin for 45 min and then incubated in goat anti-TRPV1 (1:
1000; sc-12498; SantaCruzBiotechnology) for aminimumof 48 h at 4°C.
After the primary antibody incubation, the sections were washed exten-
sively in TBS before incubation in 0.8 nm gold-conjugated donkey anti-
goat secondary antibody (1:50; Aurion) overnight at 4°C. Then the
sections were silver intensified using the R-GENT SE-LM kit according
to the protocol (Aurion). After development, the sections were treated
with 1% osmium tetroxide in PB for 10 min on ice in the dark and
dehydrated in an ascending series of ethanol and acetonitrile, before
being embedded in Durcupan (ACM; Fluka). During dehydration, sec-
tions were treated with 1% uranyl acetate in 70% ethanol for 15 min on
ice in the dark. Areas of interest from the CA1 stratum pyramidale or
stratum radiatum were reembedded and resectioned for additional elec-
tron microscopic analysis. Ultrathin (60 nm) sections were collected on
Formvar-coated single-slot grids and stained with lead citrate. Electron
micrographs were taken at 40,000magnifications with a Hitachi 7100
electron microscope. Finally, the images were collected and analyzed by
an experimenter blind to the animal genotype.
To establish the precise subcellular distribution of TRPV1 at inhibi-
tory symmetrical synapses in the hippocampal CA1 stratum pyramidale
and stratum radiatum, high-resolution quantitative evaluation was per-
formed in a population of 250 immunogold-labeled synapses in each
animal. Superficial ultrathin sections were collected at a similar tissue
depth (5 m) to ensure equal probability of antibody penetration.
Images were taken randomly of clearly identifiable symmetrical synapses
projecting onto the soma or onto the distal thin dendrites of CA1 pyra-
midal cells. If a gold particle was present in the image, its location was
determined within one of six compartments: (1) presynaptic (within the
synaptic bouton); (2) postsynaptic (directly adjacent to the bouton on
the postsynaptic cell soma); (3) somatic cytoplasmic (within the postsyn-
aptic soma but not adjacent to the synaptic bouton); (4) mitochondrial
(within mitochondria); (5) nuclear (within the cell nucleus); or (6) un-
known. The  2 tests for these subcellular compartments revealed similar
numbers of gold particles in the two animals within each genotype in all
six compartments. Therefore, data from the two animals belonging to the
same genotype were pooled and compared with data obtained from the
other genotype. The  2 tests showed significantly more gold particles in
the postsynaptic compartment of wild-type mice compared with TRPV1
knock-out animals in the case of perisomatic synapses, whereas dendritic
symmetrical synapses did not contain specific TRPV1 immunolabeling.
Gold particle numbers also did not differ between genotypes in the cat-
egories of presynaptic, somatic cytoplasmic, mitochondrial, and un-
known. More gold particles were found over the nuclei of TRPV1
knock-outmice thanwild-typemice, which likely reflects the fact that the
antibody can bind to off-targets in a nonspecific manner when its real
target protein is absent in the tissue.
To assess the subsynaptic location of these gold particles, wemeasured
their distance from the postsynaptic membrane and allocated them to
corresponding 100 nm “bins” to assess their proximity to the synapse.
Distance measurements were performed using NIH ImageJ Software.
Statistics. To analyze the data obtained from electrophysiological re-
cordings, paired or unpaired (as appropriate) two-tailed Student’s t tests
were used. In cases in which the data did not show normal distribution
based on the Shapiro–Wilk test or D’Agostino–Pearson test, then the
Wilcoxon’s signed-rank or Mann–Whitney U tests for paired and un-
paired data, respectively, were used. Pearson’s  2 tests were performed
for the validation of immunogold staining, and Kolmogorov–Smirnov
test was applied for the subcellular distribution analysis of TRPV1-
positive immunogold particles. ANOVAs were followed by Tukey–
Kramer or Dunnet’s test for mean comparisons. Data are presented as
mean 	 SEM. A p value 
0.05 was considered as significant. Statistical
analyses were performed using Origin Pro 8 and STATISTICA analysis
software.
Results
Tonic cannabinoid control on GABA release at perisomatic
synapses in the mouse hippocampus
Paired whole-cell patch-clamp recordings were performed in acute
slice preparations from identified presynaptic CB1-positive in-
terneurons and frompostsynaptic pyramidal neurons located in the
CA1 regionof themousehippocampus (n164pairs). Thepresyn-
aptic interneurons were selected based on the position of their cell
bodies in the stratum radiatum, their large soma size andmultipolar
shape, and their characteristic regular action potential firing pattern
showing prominent accommodation in response to suprathreshold
depolarizing current pulses (Fig. 1A). Importantly, each presynaptic
interneuron was filled with biocytin during the electrophysiological
recording and thenvisualized and identified after the recording (Fig.
1A).Post hoc immunostaining confirmed thepresence ofCB1 recep-
tors on the axon terminals of all recorded interneurons used in this
study (Fig. 1A).
CB1-positive interneurons with the typical regular spiking
pattern represent a morphologically heterogeneous population
of several distinct GABAergic cell types in the hippocampus,
which can be best characterized on the basis of the layer-specific
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distribution of their axonal arbors (Cope et al., 2002; Pawelzik et
al., 2002; Klausberger and Somogyi, 2008; Nissen et al., 2010;
Szabo´ et al., 2014b; Dudok et al., 2015; Lenkey et al., 2015). Re-
cently, we reported that phasic and tonic forms of synaptic endo-
cannabinoid signaling are markedly different at the output
synapses of perisomatically versus dendritically targeting in-
terneurons in the CA1 (Lee et al., 2010). Therefore, we character-
ized each interneuron according to the distribution of its axons,
and only those were included in this study that could be unequiv-
ocally classified either as a perisomatic or a dendritic cell having
an axon arbor predominantly distributed in either the stratum
pyramidale or stratum radiatum, respectively.
Action potentials in presynaptic, perisomatically projecting,
CB1-positive interneurons evoked uIPSCs in postsynaptic CA1
pyramidal neurons (Fig. 1B,E). In agreement with previous find-
ings in rats (Neu et al., 2007; Lee et al., 2010), the proportion of
presynaptic action potentials that resulted in successful postsyn-
aptic events (“successes”) and the amplitudes of euIPSCs, includ-
ing both successes and failures (Neu et al., 2007), were highly
variable between individual connections, ranging from17 to 91%
and from 7 to 120.7 pA, respectively (Fig. 1C,D,F,G). Neverthe-
less, independent analysis of two randomly selected datasets ob-
tained from perisomatic connections in our two different
laboratories (Irvine and Budapest) revealed consistently similar
mean values for both successes and euIPSC amplitudes under
control conditions. Neither the proportion of successful postsyn-
aptic events (Fig. 1C; Irvine: 63 	 9%, n  7 pairs; Fig. 1F;
Budapest: 57	 11%, n 6 pairs; t test, p 0.68) nor the ampli-
tude of euIPSCs (Fig. 1D; Irvine: 61.3	 15.4 pA, n 7 pairs; Fig.
1G; Budapest: 49.9	 15 pA, n 6 pairs; t test, p 0.6) exhibited
statistically significant differences between laboratories.
As expected from perisomatically projecting CB1-positive in-
terneurontoCA1pyramidal cell connections (Neuetal., 2007;Leeet
al., 2010), applicationof theCB1 receptor antagonist/inverse agonist
AM251 [N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-
1-piperidinyl-1H-pyrazole-3-carboxamide] (10M) unmasked the
presence of a cannabinoid tone (Fig. 1B). Both the proportion of
successful postsynaptic events (predrug control, 63	 9%; AM251,
78	 8%;Wilcoxon’s signed-rank test, p
 0.05) and the amplitude
of the euIPSCs (predrug control, 61.3	 15.4 pA; AM251, 103.1	
18.9 pA; paired t test, p 
 0.05) were significantly increased after
AM251 administration (Fig. 1C,D). Application of a lower dose of
AM251 (1 M; Fig. 1E–G) also augmented both the success rate
(predrug control, 57	 11%; AM251, 69	 8%;Wilcoxon’s signed-
rank test, p 
 0.05) and the euIPSC amplitude (predrug control,
49.9	 15 pA; AM251, 74.7	 22 pA; Wilcoxon’s signed-rank test,
p
 0.05), confirming that persistent CB1 receptor activity regulates
release probability and synaptic strength at perisomatic GABAergic
connections in the mouse hippocampus.
Constitutively active CB1 receptors control GABA release at
perisomatic synapses
Persistent receptor activity can arise from continuous ligand
availability or can be explained by a constitutively active receptor
conformation, which spontaneously signals even in the absence
of an endogenous ligand (Kenakin, 2004; Pertwee, 2005). With
the help of high-resolution biosensor imaging, the former mech-
anism, i.e., tonic 2-AG endocannabinoid activation, has been
shown recently to account for persistent CB1 receptor activity
observed on the somatodendritic surface of cultured hippocam-
pal neurons (Ladarre et al., 2014). This form of tonic CB1 activa-
tion was postulated to play an important indirect role in receptor
targeting and in the regulation of axonal CB1 numbers (Leterrier
et al., 2006). In addition, compelling evidence based on inverse
CB1 agonists used in expression systems (Bouaboula et al., 1997;
Pan et al., 1998) and in brain tissue (Mato et al., 2002) supports
Figure 1. Inverse agonist application unmasks persistent CB1 receptor activity on the axon terminals of perisomatically projecting interneurons. A, Camera lucida reconstruction shows a
perisomatically projectingGABAergic interneuron in theCA1 regionof themousehippocampus. Theneuronwas filledwithbiocytinduringelectrophysiological recording.Although thedendritic tree
(red) of this multipolar interneuron covers most hippocampal layers (Ori., stratum oriens; Pyr., stratum pyramidale; Rad., stratum radiatum), its axon arbor (blue) is restricted to the stratum
pyramidale, in which somata of CA1 pyramidal neurons are concentrated. Scale bar, 50m. Example voltage traces in response to depolarizing and hyperpolarizing current steps (200 and 150
pA, respectively, from60 mV) recorded in whole-cell patch-clamp configuration depict spike frequency adaptation typical for CB1-positive interneurons. Calibration: 30 mV, 0.3 s. Indeed,
double-immunofluorescence staining confirms that the biocytin-filled axon terminals (labeled by arrows) of this interneuron contain CB1 receptors. Scale bar, 10m. B–G, Averaged traces of
presynaptic action potentials (top) evoked in a perisomatic interneuron and the respective postsynaptic responses (bottom) in CA1 pyramidal cells. Fifty consecutive uIPSCs (gray) and their averages
(black) are presented before and during the application of the CB1 receptor antagonist/inverse agonist AM251 from the same cell pair (10MAM251 inB; 1MAM251 in E). Note the large increase
in uIPSC amplitude and success rate of GABA synaptic transmission after AM251 treatment, indicating the presence of CB1-dependent tonic signaling at this connection. Summary data showing the
proportion of successful transmissions and the euIPSC (including both failures and successes) amplitudes (10M AM251 in C, D; 1M AM251 in F, G; open circles represent individual pairs; green
filled circles label averages). Ctrl, Control.*p
 0.05.
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the notion that the latter mechanism, i.e.,
constitutive CB1 activity, may also have
biological significance. However, the
presence of constitutively active CB1 re-
ceptors on hippocampal GABAergic axon
terminals has not been substantiated. Be-
cause AM251 is a mixed antagonist/in-
verse agonist of CB1 receptors (Pertwee,
2005), we next tested the effect of the CB1
neutral antagonist NESS0327 [8-chloro-1-
(2,4-dichlorophenyl)-N-piperidin-1-yl-5,
6-dihydro-4H-benzo2,3]cyclohepta[2,4-b]
pyrazole-3-carboxamine] (Ruiu et al.,
2003) on GABAergic synaptic transmis-
sion between perisomatic CB1-positive
interneurons and postsynaptic CA1 pyra-
midal neurons (Fig. 2A). Unexpectedly,
application of NESS0327 (0.5M) did not
cause changes in the ratio of successful
postsynaptic events (Fig. 2B; predrug con-
trol, 53	 6%; NESS0327, 53	 8%; n 7
pairs; paired t test, p  0.9) and in the
amplitudes of euIPSCs (Fig. 2C; predrug
control, 47.5 	 12.5 pA; NESS0327,
48.8	 14.4 pA; n 7 pairs; paired t test,
p  0.7). In contrast, NESS0327 at the
same dose completely blocked the inhibi-
tory effect of the synthetic CB1 agonist
WIN55,212-2 [R-()-(2,3-dihydro-5-
methyl-3-[(4-morpholinyl)methyl]pyrol
[1,2,3-de]-1,4-benzoxazin-6-yl)(1-napht-
halenyl) methanone monomethanesul-
fonate] (20 nM) on GABA release from
CB1-positive perisomatic interneurons
(Fig. 2D–F; euIPSC amplitude: predrug
control, 63.6 	 16.0 pA; NESS0327 
WIN55,212-2, 59.1 	 11.1 pA; n  3
pairs; paired t test, p  0.54; successes:
predrug control, 76.4	 1.9%; NESS0327
 WIN55,212-2, 78.4 	 2.9%; n  3
pairs; paired t test, p 0.69). Importantly,
the same dose of WIN55,212-2 alone
strongly reducedGABA release fromCB1-
positive perisomatic interneurons (for de-
tails, seebelow).Moreover,NESS0327at the
samedosemostly diminishedDSI (Fig. 2G),
which isknowntobedependenton thepha-
sic activation of presynaptic CB1 receptors
by postsynaptically released 2-AG (for re-
view, see Ohno-Shosaku and Kano, 2014).
Both the proportion of successful postsyn-
aptic events (percentage of predepolariza-
tion successes: predrug control, 46.1 	
12.0%; NESS0327, 76.0 	 10.5%; paired t
test, p  0.02) and the amplitude of the
euIPSCs (percentage of predepolarization
uIPSC amplitude: predrug control, 36.3 	
14.6%; NESS0327, 66.0 	 15.7%; n  5
pairs; paired t test, p  0.03) were signifi-
cantly increased after NESS0327 administration (Fig. 2H,I).
In summary, these findings demonstrate that the neutral antag-
onist NESS0327 at a dose of 0.5 M effectively inhibits phasic CB1
activation evoked by exogenous and endogenous cannabinoids, but
it does not affect tonic cannabinoid signaling. Thus, the tonic block-
ade of neurotransmitter release probability is likely to be caused
primarily by the presence of constitutively active CB1 receptors on
perisomatic GABAergic axon terminals.
Figure 2. Neutral antagonist application inhibits phasic cannabinoid signaling, but it does not affect constitutive CB1 receptor
activity at perisomatic synapses.A, Averaged traces of presynaptic action potentials (top) evoked in a perisomatic interneuron and
the respective postsynaptic responses (bottom) in CA1 pyramidal cells illustrate that administration of the CB1 receptor neural
antagonist NESS0327 (0.5M) did not cause changes in the ratio of successful postsynaptic events and the amplitudes of euIPSCs.
Fifty consecutive uIPSCs (gray) and their averages (black) are presented before and during the application of NESS0327 (0.5M)
from the same cell pair. B, C, Summary data showing the proportion of successful transmission and the euIPSC amplitudes (open
circles represent individual pairs; black filled circles indicate averages).D, In the presence of NESS0327 (0.5M), administration of
the CB1 receptor agonistWIN55,212-2 (WIN; 20 nM) failed to cause changes in the ratio of successful postsynaptic events and in the
amplitudes of euIPSCs. E, F, Summary data showing the proportion of successful transmission and the euIPSC amplitudes (open
circles represent individual pairs; black filled circles indicate averages).G, DSIwasblockedbyNESS0327 (0.5M). DSIswere evoked
by 0.5-s-long depolarization pulses from70 to 0mV in the postsynaptic pyramidal cell. All euIPSCs were analyzed from 0 to 2 s
after the end of the pulses. Twenty consecutive control uIPSCs and their averages (black) are shown for prepulse control (before),
DSI, and full recovery (recovery). In the predrug control condition (ctrl), the depolarizing pulses almost completely reduced the
proportion of successful transmission and the euIPSC amplitudes. In the sameCB1-postive perisomatic interneuron–pyramidal cell
pair, NESS0327 (0.5 M) blocked DSIs. H, I, Summary data showing that NESS0327 significantly reduced DSIs (open circles
represent individual pairs; black filled circles indicate averages). *p
 0.05; ns, not significant.
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Tonically active monoacylglycerol lipase controls 2-AG-
mediated endocannabinoid signaling at perisomatic
GABAergic synapses
Endocannabinoid levels and the activity of their metabolizing
enzymes dynamically change according to specific physiological
states, e.g., strictly follow diurnal phases (Vaughn et al., 2010;
Liedhegner et al., 2014; Hanlon et al., 2015). Moreover, impaired
inactivation of anandamide or 2-AG attributable to reduced fatty
acid amide hydrolase (FAAH) ormonoacylglycerol lipase (MGL)
expression, respectively, leads to an elevated endocannabinoid
tone, which is often associated with pathophysiological mecha-
nisms (Sumislawski et al., 2011;Dincheva et al., 2015). Therefore,
in the next set of experiments, we aimed to determine whether
anandamide, 2-AG, or the two endocannabinoids together may
also be involved in tonic endocannabinoid signaling at periso-
matic GABAergic synapses by using pharmacological inhibitors
of endocannabinoid-degrading enzymes. As above, we used the
technically challenging and labor-intensive paired whole-cell
patch-clamp recording approach, because interference with any
aspects of endocannabinoid signaling using pharmacological
tools may trigger complex perturbations at the network level. In
addition, post hoc anatomical identification of every interneuron
was performed to ensure that ourmeasurements were focused on
the specific GABAergic connections of interest, because CB1 re-
ceptors are only present on a subset of perisomatic GABAergic
axon terminals (Katona et al., 1999). Therefore, the paired re-
cording technique has distinct advantages compared with alter-
native approaches, such as the bulk electrical stimulation of
mixed populations of fibers or the measurements of compound
spontaneous inhibitory postsynaptic events (which are derived
from more than one interneuron type). Electrophysiological
measurements were complemented by LC/MS/MS to directly
monitor changes in endocannabinoid levels in parallel with
alterations in the magnitude of the synaptic endocannabinoid
tone in similarly prepared and maintained control or drug-
treated acute hippocampal slice preparations.
MGL is responsible for the inactivation of85% of the total
2-AG content in the brain (Dinh et al., 2002; Blankman et al.,
2007). Moreover, recent studies demonstrated that this serine
hydrolase plays a regulatory role in endocannabinoid-mediated
short-term DSI (Straiker and Mackie, 2009; Pan et al., 2011).
Therefore, we first tested the effects of JZL184 (4-nitrophenyl
4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-car-
boxylate), an irreversible inhibitor of MGL (Long et al., 2009b).
Although JZL184 has a 300-fold selectivity for MGL over FAAH
(Long et al., 2009b), the primary degrading enzyme of anand-
amide, we took precautions to reduce the potential off-target
effects of this compound on anandamide levels. Besides using a
low dose (100 nM), 2-AG and anandamide levels were also mea-
sured by LC/MS/MS. The data showed that a 40 min pretreat-
ment of acute hippocampal slices with JZL184 evoked a robust
105% increase in hippocampal 2-AG levels compared with
vehicle-treated slices (Fig. 3A; paired t test, p 
 0.001; n  9
animals in each group), whereas anandamide levels did not
change significantly (Fig. 3A; paired t test, p 0.05; n 9 animals
in each group).
In accordance with the strong increase in 2-AG levels, prein-
cubation of acute hippocampal slices with JZL184 (100 nM)
Figure 3. Persistent MGL activity limits the tonic endocannabinoid control of GABA release from the axon terminals of perisomatically projecting interneurons. A, Pretreatment of acute
hippocampal slices with the irreversible MGL inhibitor JZL184 (100 nM) for 40min evoked a robust increase in hippocampal 2-AG levels as measured by LC/MS. In contrast, the same treatment had
no significant effect on anandamide levels. Data were normalized to either average control 2-AG or anandamide levels.B–D, Pretreatment of acute slices with JZL184, in amanner identical to that
used for the LC/MS measurements, strongly decreased success rates and euIPSC amplitudes. The tonic inhibitory effect of MGL blockade on GABA release was absent when JZL184 was applied
together with AM251. E, 2-AG levels were measured 5 min and 40 min after incubation of hippocampal slices in ACSF or in ACSF containing JZL184 (100 nM) by LC/MS. Unexpectedly, 2-AG levels
increased tonically under basal conditions in the absence of any pharmacological perturbation (ACSF, 5 vs 40min values are compared here). Similarly, 2-AG levelswere elevated evenmore strongly
in the presence of JZL184 (JZL184, 5 vs 40 min values are compared here). F–H, Acute administration of JZL184 (100 nM) dramatically reduced the strength of perisomatic GABAergic connections.
The drop in success rates and euIPSC amplitudes reached significance and maximal effect after 12 and 16 min, respectively, of JZL184 application. The baseline levels of success rates and euIPSC
amplitudes measured between 3 and 8min after establishment of the paired recording did not exhibit significant changes during the following 20-min-long recording period (between 23 and 28
min) in the absence of any pharmacological perturbation (ctrl, G, H ). Notably, the presence of BAPTA (10 mM) in the postsynaptic neuron or the coapplication of NESS0327 (0.5M) completely
blocked the acute effect ofMGL blockade (G,H ). InG andH, the plots show summary data of control (n 6), JZL184 (n 4), JZL184BAPTA (n 4), and JZL184NESS0327 (n 4). Error bars
were removed for clarity. Thebar graphswith error bars display summarydata at the timepoint 16min after drug application. Thenumbers of individual experiments are shown inparentheses. Error
bars represent SEM. *p
 0.05, ***p
 0.001; ns, not significant.
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caused a dramatic reduction in the strength of GABAergic trans-
mission (Fig. 3B). Both the proportion of successful postsynaptic
events (Fig. 3C; control, 58	 8%, n 11 pairs; JZL184, 17	 3%,
n 10 pairs; Tukey–Kramer test, p
 0.001) and the amplitude of
euIPSCs (Fig. 3D; control, 55.9	 12.2 pA, n 11 pairs; JZL184,
8.9 	 2.1 pA, n  10 pairs; Tukey–Kramer test, p 
 0.01) de-
creased significantly compared with vehicle-treated slices. The
effects of JZL184 were CB1 receptor mediated, because applica-
tion ofAM251 (10M) completely reversed the synaptic effects of
elevated 2-AG concentrations on the proportion of successful
transmissions (Fig. 3C; 79	 10%; Tukey–Kramer test, p
 0.001;
n  4 pairs) and on the amplitude of euIPSCs (Fig. 3D; 87.3 	
26.8 pA; Tukey–Kramer test, p 
 0.01; n  4 pairs). In accor-
dance with the plausible scenario of 2-AG acting on CB1 recep-
tors located presynaptically, the 1/CV2 value was reduced
strongly during JZL184 pretreatment (from 1.27 	 0.32 in con-
trol to 0.26	 0.07 in JZL184; Tukey–Kramer test, p
 0.05; n
11 and 10 pairs), which was rescued by AM251 application
(1.73	 0.6; Tukey–Kramer test, p
 0.05; n 4 pairs).
These mass spectrometry and electrophysiology results indi-
cated that 2-AG is mobilized constitutively in acute hippocampal
slice preparations. To investigate more directly this possibility,
we measured 2-AG levels in the absence of any pharmacological
perturbation. Surprisingly, acute hippocampal slices produced
2-AG even under basal conditions, because comparison of two
sets of samples kept in ACSF revealed 41% higher 2-AG levels in
slices snap-frozen at a later time point (35min; Fig. 3E).MGL can
partially keep the tonic elevation of 2-AG levels under control,
because the same measurement in the presence of JZL184 (100
nM) resulted in a much larger increase in 2-AG levels (89%; Fig.
3F). Next, we aimed to test directly the effect of the tonic release
of 2-AG on GABAergic transmission. After establishing stable
paired recording between a CB1-positive perisomatic interneu-
ron and a CA1 pyramidal neuron, the baseline levels of successes
and euIPSCs were measured, and then the effect of acute admin-
istration of JZL184 (100 nM) was followed through 20 min. No-
tably, blockade of MGL significantly reduced the strength of
perisomatic GABAergic connections within 12 min of JZL184
application (Fig. 3F–H). Themaximal decrease in the proportion
of successful postsynaptic events was down to 23 	 6% of the
baseline levels (Fig. 3G), whereas the amplitude of euIPSCs was
dropped to 29 	 8% of the baseline values (Fig. 3H) at 16 min
after drug application (one-way ANOVA with repeated mea-
sures; n 4 pairs, p
 0.001 for both parameters).
Previous studies provided direct evidence that tonic endocan-
nabinoid signaling is a homosynaptic phenomenon (Hentges et
al., 2005; Zhu and Lovinger, 2005; Neu et al., 2007; Roberto et al.,
2010). In these studies, the increased GABAergic synaptic trans-
mission observed in the presence of 10 M AM251 could be
blocked by calcium chelation in the postsynaptic neuron. There-
fore, we also recordedGABAergic events by using an intracellular
pipette solution containing 10 mM BAPTA. Remarkably, the
presence of BAPTA in the postsynaptic neuron vetoed the acute
effect ofMGLblockade (Fig. 3G,H), demonstrating that the post-
synaptic neuron is tonically releasing 2-AG, which then affects
GABA release probability in a homosynaptic manner. Specifi-
cally, both the success rate (95 	 1% of baseline values; n  4
pairs) and the euIPSC amplitude (86	 1%of baseline values;n
4 pairs) remained unchanged (one-way ANOVA with repeated
measures; n  4 pairs, p  0.05 for both parameters), when the
MGL inhibitor was applied in the presence of BAPTA in the
pipette that was used to record the uIPSCs from the postsynaptic
cell. Finally, to fully exclude any potential confounding effect of
inverse agonismbyAM251, the neutral antagonistNESS0327was
used to prove unequivocally that tonic 2-AG activation of CB1
receptors was necessary to diminish GABAergic synaptic trans-
mission (Fig. 3G,H). Indeed, when NESS0327 (0.5 M) was co-
applied with JZL184 (100 nM), neither the proportion of
successful postsynaptic events (control, 92	 5% of baseline val-
ue; JZL184  NESS0327, 94 	 8%; n  4 pairs) nor the ampli-
tude of euIPSCs (control, 82.6	 9.2 pA of baseline value; JZL184
 NESS0327, 84.1 	 15.2 pA; n  4 pairs) were changed (one-
way ANOVA with repeated-measures; p  0.05 for both
parameters).
Collectively, these findings demonstrate that 2-AG is gener-
ated constitutively in acute hippocampal slice preparations and
that tissue levels of 2-AG are under the tonic control of MGL
activity. As a result, persistentMGL activity plays a critical role in
setting the strength of GABAergic synaptic transmission at the
CB1-expressing GABAergic perisomatic inputs to pyramidal
cells.
FAAH does not regulate tonic anandamide signaling at
perisomatic GABAergic synapses
In accordance with the distinctive role of anandamide signaling
in certain behavioral processes (Long et al., 2009a), emerging
evidence indicates that specific forms of phasic and tonic endo-
cannabinoid signaling at given brain circuit locations or under
specific physiological conditions are mediated by anandamide
(Azad et al., 2004; Kim and Alger, 2010; Huang and Woolley,
2012; Lerner and Kreitzer, 2012; Khlaifia et al., 2013; Mathur et
al., 2013). Therefore, we next sought to determine whether anan-
damide is also involved in tonic endocannabinoid signaling at
perisomatic GABAergic synapses in the mouse hippocampus. As
mentioned above, the predominant degrading enzyme of anan-
damide is FAAH (Cravatt et al., 1996). Blockade of FAAH with
the recently introduced selective inhibitor PF3845(N-pyridin-
3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]
piperidine-1-carboxamide) (Ahn et al., 2009) at 1 M evoked a
striking and selective increase in anandamide levels by 107% (Fig.
4A; paired t test, p 
 0.001; n  4 animals) but was unable to
cause significant changes in 2-AG levels (Fig. 4A; paired t test, p
0.05; n 4 animals). Throughout this study, PF3845 was used to
perturb anandamide signaling because of its high selectivity for
FAAH inhibition. For comparison purposes, the pretreatment
effects of another widely used FAAH inhibitor, URB597 [3-
(aminocarbonyl)[1,1-biphenyl]-3-yl)-cyclohexylcarbamate] (1
M; Kathuria et al., 2003), on endocannabinoid levels were also
measured. Similar to PF3845, URB597 also caused a large in-
crease (103%) in anandamide levels (Fig. 4A; paired t test, p 

0.05; n 5 animals) but not in 2-AG levels (Fig. 4A; paired t test,
p 0.05; n 5 animals).
Despite the highly elevated levels of anandamide, paired re-
cordings from presynaptic perisomatically projecting CB1-
positive interneurons and postsynaptic CA1 pyramidal neurons
(Fig. 4B) revealed that the proportion of successful postsynaptic
events (Fig. 4C; control, 60	 7%, n 14 pairs; PF3845, 56	 8%,
n  12 pairs; unpaired t test, p  0.05) and the amplitude of
euIPSCs (Fig. 4D; control, 56.6	 9.5 pA, n 14 pairs; PF3845,
54.9 	 15.7 pA, n  12 pairs; Mann–Whitney U test, p  0.05)
remained unchanged in the presence of PF3845 (1 M).
These data together show that anandamide is also constitu-
tively generated in hippocampal slice preparations and its tissue
level is tonically controlled by FAAH activity. However, in con-
trast to the effects of the elevated 2-AG levels, highly increased
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anandamide levels have no direct effect on the strength of neu-
rotransmission at perisomatic GABAergic synapses.
Neither MGL nor FAAH regulates GABA release at dendritic
inhibitory synapses
Tonic endocannabinoid signaling is not present at the efferent
synapses of dendritically projecting CA1 interneurons, despite
the fact that the axon terminals of these interneurons do possess
functional CB1 receptors (Lee et al., 2010). This was especially
surprising because diacylglycerol lipase- (DGL-), the synthe-
sizing enzyme of 2-AG (Bisogno et al., 2003), is concentrated
mainly in the dendritic spine heads of pyramidal neurons (Ka-
tona et al., 2006; Yoshida et al., 2006). The finding that MGL
tonically controls the synaptic effects of 2-AG at perisomatic
GABAergic synapses raised the possibility that elevated MGL ac-
tivity in dendritically projecting interneuron boutons couldmask
the presence of a weak tonic 2-AG effect at dendritic GABAergic
synapses. To test this possibility, paired recordings were per-
formed from presynaptic dendritically projecting CB1-positive
interneurons (Fig. 5A) and postsynaptic CA1 pyramidal neurons
in acute hippocampal slices.
First, we tested the functionality of presynaptic CB1 receptors
on dendritic connections (Fig. 5B) by applying a very low dose of
the synthetic CB1 agonistWIN55,212-2 (20 nM), which could still
readily reduce the success rate by 19	 7% (Fig. 5C; n 6 pairs;
Wilcoxon’s signed-rank test, p 
 0.05) and the euIPSC ampli-
tudes by 35	 6% (Fig. 5D; n 6 pairs; Wilcoxon’s signed-rank
test, p 
 0.05). As expected (Lee et al., 2010), the same dose of
WIN55,212-2 (20 nM) had significantly larger effects on periso-
matic connections (for both parameters, Mann–Whitney U test,
p
 0.05). The proportion of successful postsynaptic events orig-
inating from perisomatically projecting interneurons was inhib-
ited by 42	 9% (Fig. 5C; n 7 pairs; paired t test, p
 0.01), and
the euIPSC amplitudes were decreased by 61	 7% (Fig. 5D; n
7 pairs; Wilcoxon’s signed-rank test, p
 0.05). Despite the latter
data demonstrating the presence of functionally active CB1 re-
ceptors on the axon terminals of dendritically projecting in-
terneurons, application of 1 or 10 M AM251 could not uncover
the presence of persistent CB1 activity on these axon terminals
(Fig. 5E–J), in agreement with our previous findings in rats (Lee
et al., 2010). Both the proportion of action potentials evoking
successful postsynaptic events (predrug control, 80	 7%; 1 M
AM251, 76	 7%; n 3 pairs, Wilcoxon’s signed-rank test, p
0.05; predrug control, 58	 6%; 10 M AM251, 60	 8%; n 4
pairs, Wilcoxon’s signed-rank test, p 0.05) and the amplitude
of the euIPSCs (predrug control, 48 	 6.8 pA; 1 M AM251,
43.7	 4.9 pA; n 3 pairs,Wilcoxon’s signed-rank test, p 0.05;
predrug control, 20.5 	 2.9 pA; 10 M AM251, 20.1 	 1.7 pA;
n  4 pairs, Wilcoxon’s signed-rank test, p  0.05) remained
unchanged after AM251 administration.
In the next set of experiments, acute hippocampal slice prep-
arations were pretreated with either vehicle or theMGL inhibitor
JZL184 (100 nM; Fig. 5K). However, neither the proportion of
successful postsynaptic events (Fig. 5L; control, 57	 12%, n 5
pairs; JZL184, 57 	 11%, n  4 pairs; Tukey–Kramer test, p 
0.05) nor the amplitude of euIPSCs (Fig. 5M; control, 27.2	 13.0
pA, n  5 pairs; JZL184, 33.8 	 18.4 pA, n  4 pairs; Tukey–
Kramer test, p 0.05) were changed significantly after blockade
of MGL activity by JZL184 at dendritic connections. Given that
the axon terminals of both perisomatically and dendritically pro-
jecting interneurons contain CB1 receptors (Figs. 1A, 5A), the
presence of tonic 2-AG signaling at perisomatic, but not at den-
dritic, GABAergic synapses raised the possibility of an input-
specific functional segregation between 2-AG and anandamide
signaling. Thus, we also investigated the possibility whether tonic
FAAH activity may regulate tonic anandamide signaling at den-
dritic GABAergic synapses. However, application of the FAAH
inhibitor PF3845 (1M) did not affect the proportion of success-
ful postsynaptic events (Fig. 5L; control, 57	 12%, n 5 pairs;
PF3845, 56	 12%, n 4 pairs; Tukey–Kramer test, p 0.05) or
the amplitude of euIPSCs (Fig. 5M; control, 27.2	 13.0 pA, n
5 pairs; PF3845, 21.9	 5.6 pA, n 4 pairs; Tukey–Kramer test,
p 0.05) in dendritically projecting, CB1-expressing interneuron
to pyramidal cell synapses.
These observations indicate the absence of constitutive CB1 ac-
tivity, tonic endocannabinoid signaling, and the lack of functionally
detectable tonic MGL and FAAH activities at dendritic GABAergic
synapses in themousehippocampus.The interneuron-type specific-
ity of tonic 2-AG signaling also indicates that the robust JZL184
effect on perisomatic GABAergic synaptic transmission was not the
consequence of unidentified nonspecific network mechanisms be-
cause of a potential elevation of 2-AG throughout the hippocampal
tissue.
Increased endocannabinoid tone affects synaptic functions
without changing the number of presynaptic CB1 receptors
The above results were somewhat unexpected considering the
general view that anandamide may be better suited to serve as a
tonic endocannabinoid signal (Alger, 2012; Ohno-Shosaku and
Kano, 2014; Piomelli, 2014). This notion is based in part on the
Figure 4. FAAH does not directly mediate tonic endocannabinoid signaling at CB1-
expressingperisomatic GABAergic synapses.A, Preventionof anandamide inactivationbyusing
the selective FAAH inhibitor PF3845 (1M; 40min) resulted in a large increase in hippocampal
anandamide levels, whereas 2-AG levels remained unaffected in acute hippocampal slice prep-
arations. Pretreatment with a second independent FAAH inhibitor, URB597 (1 M; 40 min),
caused a similar rise in anandamide levels, whereas 2-AG levels did not change. Data were
normalized to either average control 2-AG or anandamide levels. B–D, Despite the elevated
anandamide levels in hippocampal slices, inhibition of FAAHbyPF3845pretreatment (1M; 40
min) did not alter success rates or euIPSC amplitudes at perisomatic synapses. The numbers of
individual experiments are shown inparentheses. Error bars represent SEM. *p
0.05, ***p

0.001; ns, not significant; ctrl, control.
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slower time course of anandamide mobilization and the fact that
anandamide displays partial agonism toward CB1, in contrast to
2-AG, which is a full agonist (Stella et al., 1997; Hillard, 2000). In
accordance with this view, chronic elevations of 2-AG levels by
long-term pharmacological or genetic blockade of MGL activity
causes robust behavioral tolerance as a result of the massive
downregulation of CB1 receptors, whereas chronically increased
anandamide levels attributable to the inhibition of FAAH do not
evoke similar adaptive responses (Schlosburg et al., 2010). These
findings obtained at the systems level also suggest that any exper-
imental perturbation that increases endocannabinoid levels may
also indirectly affect CB1 receptor availability. Thus, any mea-
sured changes in synaptic strength could simply be the conse-
quence of a change in receptor numbers.
We tested the possibility of alterations in receptor numbers
after the increase in endocannabinoid tone using STORM
super-resolution imaging (Rust et al., 2006; Dani et al., 2010;
Dudok et al., 2015) at CB1 receptor-expressing perisomatic
synapses onto CA1 pyramidal cells, i.e., at the synapse type
that exhibits tonic endocannabinoid-mediated inhibition of
GABA release. CB1-positive perisomatic interneurons were
filled with biocytin during patch-clamp recordings in either
vehicle-treated or enzyme (MGL or FAAH) inhibitor-treated
acute hippocampal slices. The CB1 content of the biocytin-
labeled axon terminals of interneurons was analyzed at the
nanoscale level to distinguish surface and internalized recep-
tors (Fig. 6A). Because the vast majority of CB1 receptors are
found in the plasma membrane (Nyíri et al., 2005), fitting a
convex hull onto the outermost LPs representing CB1 recep-
tors could reliably identify the receptor population on the
axon terminal surface (Dudok et al., 2015). Notably, an anal-
ysis of the nanoscale distribution of CB1 receptors in 303 in-
Figure 5. Blockade of endocannabinoid degradation does not affect synaptic functions at GABAergic synapses formed by CB1-expressing dendritically projecting interneurons. A, Camera lucida
reconstruction illustrates a CB1-positive dendritically projecting GABAergic interneuron in the CA1 region of the mouse hippocampus. The dendrites (red) and most of the axons (blue) of this
multipolar interneuron arborized in stratum radiatum (Rad.), but a fewadditional axonbrancheswere also observed in the stratumpyramidale (Pyr.) and stratumoriens (Ori.). Scale bar, 50m.The
example voltage traces in response to depolarizing and hyperpolarizing current steps (100 and 150 pA, respectively, from60mV) show a characteristic regular spiking patternwith prominent
spike frequency adaptation, an electrophysiological fingerprint of CB1-positive interneurons. Calibration: 30 mV, 0.3 s. Confocal images demonstrate that the biocytin-filled boutons (labeled by
arrows) of this interneuron are indeed CB1 positive. Scale bar, 10m.B, Representative traces demonstrate that a low dose of the synthetic CB1 agonist WIN55,212-2 (20 nM) significantly reduced
synaptic strength at both dendritic and perisomatic GABAergic connections. C, D, Application of WIN55,212-2 reduced the success rates and euIPSC amplitudes more strongly at perisomatic
connections. E–J, Application of neither 1M AM251 nor 10M AM251 unmasked persistent CB1 activity on the axon terminals of CB1-expressing dendritic interneurons. K, Despite the presence
of functional CB1 receptors on theaxon terminals, GABAergic synaptic transmissionoriginating fromdendritic interneurons is not affectedby inhibitingendocannabinoidhydrolysis byeither theMGL
inhibitor JZL184 (100 nM; 40min) or the FAAH inhibitor PF3845 (1M; 40min). L,M, Neither the proportion of successful postsynaptic events nor the amplitude of euIPSCs were altered by JZL184
or PF3845 pretreatment, indicating that the absence of dendritic tonic inhibition is not attributable to highMGL or FAAH activity at dendritic connections. The numbers of individual experiments are
shown in parentheses. Error bars represent SEM. *p
 0.05, **p
 0.01; ns, not significant.
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dividual axon terminals from 13 identified perisomatically
projecting interneurons revealed no significant changes in the
total receptor number (Fig. 6B) or in the ratio of internalized/
surface membrane CB1 receptors (Fig. 6C) after JZL184 (100
nM) or PF3845 (1 M) application for similar amounts of time
as in the electrophysiological experiments described above (40
min; Tukey–Kramer test, p  0.05 in all four measurements,
n  7 vehicle-treated cells compared to 3–3 JZL184- or
PF3845-treated cells). These observations demonstrate that
the pretreatment protocol used in the present study does not
cause a change in CB1 receptor numbers on perisomatic
GABAergic axon terminals, despite the strong increase in en-
docannabinoid levels attributable to the blockade of endocan-
nabinoid degradation.
Tonic anandamide signaling interacts with tonic
2-AG signaling
The biological rationale of why the brain needs two endocannabi-
noidmessengers is not fully understood (DiMarzo andDePetrocel-
lis, 2012). A potential clue may be that the remarkable biochemical
diversity of endocannabinoid synthesis routes (Blankman and Cra-
vatt, 2013) provides an opportunity for specific signaling mecha-
nisms to selectively recruit endocannabinoid synthesis under certain
physiological or pathophysiological conditions. This also raises the
possibility that coincident physiological signalsmay sometimes trig-
ger the mobilization of both endocannabinoids at the same time,
which then interact with each other.
Therefore, in the next set of experiments, we asked the
question whether tonic 2-AG signaling at perisomatic GABAe-
rgic synapses could be fine-tuned by anandamide signaling.
One potential explanation for the lack of effects of FAAH
inhibition on GABAergic synaptic strength could stem from
the fact that anandamide, as mentioned above, is a partial
agonist of CB1, and hence it may not elicit a response by itself
at these specific GABAergic synapses. As a consequence, it may
either facilitate or occlude the effects on tonic 2-AG signaling
depending on how 2-AG saturates the functionally relevant
CB1 receptor pool on the axon terminals. Indeed, in paired
recordings from CB1-positive perisomatic interneurons and
CA1 pyramidal neurons (Fig. 7A), whenMGL and FAAH were
inhibited simultaneously by JZL184 (100 nM) and PF3845 (1
M), both the proportion of successful postsynaptic events
(Fig. 7B; JZL184, 17 	 3%, n  10 pairs; JZL184  PF3845,
41 	 8%, n  6 pairs; unpaired t test, p 
 0.05) and the
amplitude of euIPSCs (Fig. 7C; JZL184, 8.9 	 2.1 pA, n  10
pairs; JZL184 PF3845, 37.9	 11.0 pA, n 6 pairs; unpaired
t test, p 
 0.05) were significantly larger compared with the
selective blockade of MGL with JZL184 alone. Thus, this ob-
servation demonstrates that, although enhanced anandamide
signaling is not effective in itself, it can readily interfere with
tonic 2-AG signaling at perisomatic GABAergic synapses.
These findings may result from an occlusion of 2-AG effects
on presynapticCB1 activation by anandamide.However, the facts
that FAAH is postsynaptic, whereas MGL is presynaptic (Gulya´s
Figure 6. Acute inhibition of endocannabinoid-degrading enzymes does not affect CB1 numbers on the plasma membrane of perisomatic interneuron boutons. A, CB1-positive perisomatic
interneurons were filled with biocytin in acute hippocampal slice preparations that were pretreated with vehicle (0.1% DMSO; 40 min), JZL184 (100 nM; 40 min), or PF3845 (1M; 40 min) to
determine whether increased 2-AG or anandamide levels affect the number of CB1 receptors on perisomatic axon terminals. Deconvolved confocal images of identified boutons of perisomatic
interneurons that were visualized by biocytin labeling (orange) are shown together with the corresponding STORM images of CB1 immunostaining. LPs (green dots) in the raw STORM images
represent the position of CB1 receptors in the axon terminals. To analyze the nanoscale distribution of CB1 receptors, individual LPs were first visualized in 3D and illustrated using Visual Molecular
Dynamics. Based on the acquired 3D localization coordinates, a convex hull was then fitted onto the outermost CB1 LPs to approximate the plasmamembrane. To distinguish membrane-attached
LPs (green) and those that are likely intracellular receptors located away from the surface of the convex hull (blue), an internalization index was calculated (for details, see Materials andMethods).
B, C, Summary data of the STORM super-resolution imaging experiment reveals that neither the total number of CB1 LPs nor the proportion of intracellular CB1 LPs are changed significantly by
pretreatment of MGL or FAAH inhibitors, indicating that any observed changes in synaptic functions during pharmacological treatments are not attributable to an altered number of available CB1
receptors on the axon terminal surface. The number of individual experiments is shown in parentheses. Datawere normalized to average control CB1 number of localization points (NLP) values. Error
bars represent SEM. ns, Not significant; Ctrl, Control.
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et al., 2004), and that brain 2-AG concentrations are 170 times
greater than anandamide concentrations (Stella et al., 1997) do
not support this scenario. Conversely, DGL-, the synthesizing
enzyme of 2-AG, also occurs postsynaptically in the somatoden-
dritic domain of pyramidal neurons, in which FAAH is located
(Gulya´s et al., 2004; Katona et al., 2006; Yoshida et al., 2006). This
molecular architecture indicates that postsynaptic elevation of
anandamide levels may interfere with the postsynaptic mobiliza-
tion of 2-AG. Indeed, coapplication of JZL184 (100 nM) with
PF3845 (1 M) significantly reduced the increase in 2-AG levels
compared with MGL blockade alone (Fig. 7D; paired t test, p 

0.05; n  5 slices). In striking contrast, increased anandamide
levels induced by PF3845 pretreatment were not attenuated by
the coapplication of PF3845 with JZL184 (Fig. 7E; paired t test,
p 0.05; n 5 slices).
Together, these results uncovered that tonic 2-AG signaling
at perisomatic GABAergic synapses in the hippocampus are
controlled by the anandamide-degrading enzyme FAAH via
potential postsynaptic interaction mechanisms affecting 2-AG
synthesis.
TRPV1 channels are located on intracellular membrane
cisternae at perisomatic symmetrical synapses
To explore howpostsynaptic anandamide signalingmay interfere
with tonic retrograde 2-AG signaling, in the final set of experi-
ments, we tested the hypothesis whether TRPV1 receptors repre-
sent a link between the two lipid signaling pathways at
hippocampal GABAergic synapses. TRPV1 appeared to be a po-
tential candidate, because anandamide is a full agonist of TRPV1
(Zygmunt et al., 1999), and anatomical evidence at the light mi-
croscopic level shows that TRPV1 is present in the somatoden-
dritic domain of CA3 pyramidal neurons together with FAAH
(Cristino et al., 2008). In addition, emerging evidence indicates
that anandamide signaling elicits synaptic plasticity via postsyn-
aptic TRPV1 activation in other brain areas (Cha´vez et al., 2010,
2014; Grueter et al., 2010; Puente et al., 2011), and, most impor-
tantly, anandamide inhibits metabotropic glutamate receptor-
induced 2-AG synthesis and phasic endocannabinoid signaling in
the striatum via TRPV1 activation (Maccarrone et al., 2008).
Although recent evidence showed that TRPV1 is found post-
synaptically at excitatory synapses (Puente et al., 2011, 2015),
there was no direct evidence as to whether this ion channel is also
located at hippocampal GABAergic synapses, which would be a
prerequisite for it to serve as the regulator of tonic endocannabi-
noid signaling at perisomatic inhibitory synapses. Therefore, we
used immunogold electron microscopy to study the localization
of TRPV1 at symmetrical synapses in the stratumpyramidale and
stratum radiatumof the CA1 subregion of the hippocampus (Fig.
8A,B). Inwild-typemice, immunogold particles representing the
position of TRPV1 were found frequently in the cell body of CA1
pyramidal neurons (Fig. 8A). Moreover, the subcellular distribu-
tion analysis of TRPV1 immunolabeling revealed a significant
population of this ion channel postsynaptically, adjacent to sym-
metrical, putativeGABAergic synapses in the stratumpyramidale
(Fig. 8A,C). In contrast, immunogold particles were found only
occasionally in the latter postsynaptic compartment in TRPV1
knock-outmice (Fig. 8B,C), validating the specificity of the post-
synaptic distribution pattern of TRPV1 at inhibitory synapses
(Pearson’s 2 test, p 
 0.001; n  429 and 445 synapses in two
wild-type and two knock-outmice, respectively). Specific TRPV1
immunolabeling was not found in the presynaptic GABAergic
axon terminals or on mitochondria. Analysis of single 60 nm
ultrathin sections, including normalization of the data to the
nonspecific labeling within the same compartment in TRPV1
knock-out mice, revealed that 18% of perisomatic GABAergic
synapses were positive for TRPV1. Given the size of CB1-positive
perisomatic symmetrical synapses, which span several consecu-
tive ultrathin sections, and considering their proportion among
all symmetrical synapses in the stratum pyramidale of the CA1 sub-
field (35–40%; Taka´cs et al., 2015), our data are consistent with the
possibility that most, if not all, CB1-positive perisomatic synapses
contain postsynaptic TRPV1 channels. Conversely, no significant
differencewas detected in the ratio of immunogold-containingden-
driticGABAergic synapses in the stratumradiatumbetweenWTand
TRPV1 knock-out mice (6.08 and 3.7%; n 115 and 108 dendritic
synapses, respectively; p 0.41, 2 test).
The precise subcellular localization of the nonselective cation
channel TRPV1 has also functional significance. Therefore, we
Figure7. Antagonistic interaction of endocannabinoid-degradingpathways fine-tunes tonic endocannabinoid signaling at CB1-positive perisomatic GABAergic synapses.A, Example traces of 50
consecutive postsynaptic events (bottom; individual uIPSCs are gray; averages are black) evoked by presynaptic action potentials (top) in CB1-positive perisomatically projecting interneurons
demonstrate that the low synaptic efficiency of GABAergic transmission induced by pretreatmentwith theMGL inhibitor JZL184 (100 nM; 40min) can be enhanced significantly by the simultaneous
inhibition of FAAHactivity (PF3845; 1M; 40min).B, C, Both the proportion of successful synaptic events and the amplitude of euIPSCswere notably largerwhen JZL184was coappliedwith PF3845
comparedwith JZL184 applied alone.D, Prevention of the hydrolysis of both endocannabinoids resulted in significantly smaller levels of 2-AG comparedwith the effects of MGL inhibition alone. E,
In contrast, coapplication of the two serine hydrolase inhibitors did not attenuate anandamide levels induced by PF3845 treatment alone. Datawere normalized to either average 2-AG levels in the
presence of JZL184 or average anandamide levels in the presence of PF3845. The numbers of individual experiments are shown in parentheses. Error bars represent SEM. *p
 0.05; ns, not
significant.
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first measured the distance of individual
gold particles from the synapse. In total,
68% of gold particles were found adjacent
to symmetrical synapses (within 200 nm),
which was significantly different from the
background distribution observed in
knock-out animals (Fig. 8D; Kolmogoro-
v–Smirnov test, p
 0.001; n 128 and 33
gold particles from two wild-type and two
knock-out mice, respectively). Surpris-
ingly, the majority of gold particles repre-
senting the subcellular position of TRPV1
was found to be attached to intracellular
membrane cisternae (Fig. 8A1,A2) instead
of a plasma membrane localization (55	
6 vs 18 	 4%). The subcellular compart-
ment of the remaining 27 	 2% of gold
particles could not be identified unequiv-
ocally in the absence of clearly outlined
nearby membranes, but these particles
were all away from the plasmamembrane.
Considering that TRPV1 is an integral
membrane channel and that those gold
particles that were found close to the
plasma membrane may also have be-
Figure 8. TRPV1 is present postsynaptically at perisomatic GABAergic synapses and regulates synaptic strength at CB1-
expressing perisomatic GABAergic synapses. A, At the electron microscopic level, immunogold staining revealed that TRPV1
channels are located postsynaptically at perisomatic GABAergic synapses (labeled by asterisk) formed on the somata of CA1
pyramidal neurons in wild-type mice. A1, A2, Higher-magnification electron micrographs show that gold particles
4
representing the position of TRPV1were often attached to pu-
tative intracellular membrane cisternae (highlighted with
black line inA2).B, In contrast, postsynaptic immunogold par-
ticles were usually not located at symmetrical GABAergic syn-
apses obtained from TRPV1 knock-out mice. C, Summary bar
graph illustrates that the proportion of randomly selected
GABAergic synapses forming symmetrical synapses on the cell
bodies of CA1 pyramidal neurons that contained immunogold
particles in close proximity to the synapse was significantly
higher on sections derived from wild-type mouse hippocam-
pus comparedwith that obtained fromTRPV1 knock-outmice.
D, To assess the subsynaptic distribution of TRPV1 channels,
immunogold particle distribution was further analyzed by
measuringdistanceof eachgoldparticle fromthepostsynaptic
membrane. Notably, a sharply biased distribution of gold par-
ticles toward the postsynaptic membranewas observed. Alto-
gether, 68% of all gold particles were found in the vicinity of
the postsynaptic plasmamembrane (
200 nm) and six times
more gold particles were found in wild-type versus TRPV1
knock-out animals in the first two 100 nm bins. E, In accor-
dancewith these anatomical findings, coapplication of the se-
lective TRPV1 antagonist AMG9810 (1 M; 40 min) could
efficiently rescue the effect of the FAAH inhibitor on 2-AG-
mediated tonic inhibition of GABA release. F, G, Both the ratio
of successful postsynaptic events and theamplitudeof euIPSCs
decreased significantly when AMG9810 was applied together
with JZL184 and PF3845 compared with those when JZL184
and PF3845 were applied alone. H–J, MGL blockade with
JZL184 (100 nM) strongly reduced success rate and euIPSCs
compared with vehicle treatment (ctrl) in TRPV1 knock-out
animals. However, the antagonistic effect of FAAH inhibition
(seen in F and G in wild-type animals) was completely absent
in TRPV1 knock-out mice (H). Importantly, when JZL184 (100
nM) was applied alone or together with PF3845 (1 M), the
success rate of action potentials evoking a postsynaptic IPSC
and the amplitude of euIPSCs did not differ between the two
conditions. The number of individual experiments is shown in
parentheses. Error bars represent SEM. *p
 0.05, ***p

0.001; ns, not significant; Ctrl, control.
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longed to intracellular membrane segments that were not identi-
fiable, these data suggest that a surprisingly high proportion of
TRPV1 is present on intracellular membrane compartments posi-
tioned under the postsynaptic plasma membrane of GABAergic
synapses.
Endovanilloid signaling acting on postsynaptic TRPV1
channels regulates tonic 2-AG signaling on presynaptic CB1
receptors
Ourelectronmicroscopicfindingsrevealedthatthesubcellulardistribu-
tionofTRPV1 is similar to the compartmentalized subcellular localiza-
tionofFAAHonintracellularmembranecisternae (Gulya´s et al., 2004).
Therefore,we tested the hypothesis thatTRPV1maybe responsible for
the functional interaction of FAAH inhibition with tonic 2-AG-
mediated endocannabinoid signaling by using pharmacological and
genetic tools. Paired recordings from perisomatically projecting in-
terneurons and pyramidal neurons (Fig. 8E) revealed that the spe-
cific TRPV1 inhibitor AMG9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide] (Gavva et al., 2005)
completely rescued the effectof theFAAHinhibitorPF3845on tonic
2-AG signaling.When AMG9810 (1M) was applied together with
JZL184 (100 nM) and PF3845 (1M), both the success rate of action
potentials evoking a postsynaptic IPSC (Fig. 8F; JZL184 PF3845,
41	8%,n6pairs; JZL184PF3845AMG9810, 16	6%,n
5pairs; unpaired t test, p
 0.05) and the amplitude of euIPSCs (Fig.
8G; JZL184  PF3845, 37.9 	 11.0 pA, n  6 pairs; JZL184 
PF3845AMG9810, 6.2	 1.0 pA, n 5 pairs; unpaired t test, p

0.05) were decreased significantly. Accordingly, the proportion of
successful events and the amplitude of euIPSCs were similar in the
presence of theMGL inhibitor alone and when JZL184 was applied
together with PF3845 andAMG9810 (unpaired t test, p 0.05; n
10 and 5 pairs). As a control, to exclude the possibility that the in-
hibitory effect ofAMG9810on theFAAHinhibitorPF3845-induced
decrease in tonic 2-AG signaling is confoundedby someunexpected
off-target effects of AMG9810, we also tested whether AMG9810
attenuates GABA release from CB1-positive perisomatic interneu-
rons in a CB1-dependent or CB1-independent manner. Our paired
recordings revealed that pretreatment with AMG9810 (1 M), in
neither the absence nor the presence of the CB1 receptor antagonist
AM251 (10 M), affected the proportion of action potentials evok-
ing a postsynaptic IPSC (vehicle, 60	 7%, n 9 pairs; AMG9810,
65	 8%, n 8 pairs; unpaired t test, p 0.05; AM251, 92	 5%,
n 3 pairs; AMG9810 AM251, 93	 2%, n 3 pairs; AM251,
92	 5%, n 3 pairs; unpaired t test, p 0.5) and the amplitude of
euIPSCs (vehicle, 53.1	 10 pA, n 9 pairs; AMG9810, 66.4	 16
pA, n 8 pairs; unpaired t test, p 0.05; AM251, 160.4	 22.8 pA,
n  3 pairs; AMG9810  AM251, 150.8 	 15.5 pA, n  3 pairs;
unpaired t test, p  0.5). In accordance with the above electron
microscopic observation that the level of TRPV1 channels are under
detection threshold at dendritic synapses, preincubation of
AMG9810 alone did not have any apparent effect on the pro-
portion of successful postsynaptic events (vehicle, 68 	 7%,
n  6 pairs; AMG9810, 69 	 3%, n  4 pairs; unpaired t test,
p  0.86) and the amplitude of euIPSCs (vehicle, 33.5 	 7.3
pA, n  6 pairs; AMG9810, 37.3 	 4.2 pA, n  4 pairs; un-
paired t test, p 0.66) at dendritic connections. Furthermore,
application of AM251 (10 M) did not unmask persistent CB1
activity in slices pretreated with AMG9810 (successes: 73	 4%,
n 4 pairs, paired t test, p 0.3; euIPSCs amplitudes: 34.4	 2.5
pA, n  4 pairs, paired t test, p  0.57). Thus, these control
experiments indicate that the observed inhibition of the FAAH
inhibitor-induced decrease in tonic 2-AG signaling by AMG9810
was mediated directly by TRPV1 blockade and that this interac-
tion occurs selectively at perisomatic synapses.
Finally, to corroborate the involvement of TRPV1 in the func-
tional interaction between FAAH activity and MGL activity,
paired patch-clamp recordings and pharmacological treatments
were performed in acute hippocampal slices obtained from
TRPV1 knock-out mice. Notably, MGL blockade robustly re-
duced success rate and euIPSCs in both wild-type and TRPV1
knock-out animals (Figs. 3B–D, 8H–J), but the antagonistic ef-
fect of FAAH inhibition in wild-type animals (Fig. 7A–C) was
completely absent in TRPV1 knock-out mice (Fig. 8H–J). When
JZL184 (100 nM) was applied alone or together with PF3845 (1
M), both the success rate of action potentials evoking a postsyn-
aptic IPSC (Fig. 8I; JZL184, 21 	 6%, n  5 pairs; JZL184 
PF3845, 22 	 6%, n  5 pairs) and the amplitude of euIPSCs
(Fig. 8J; JZL184, 12.6 	 3.2 pA, n  5 pairs; JZL184  PF3845,
8.7	 3.3 pA, n 5 pairs) were decreased significantly compared
with control values obtained in TRPV1 knock-out mice (Fig. 8I;
successes: 74 	 11%, n  5 pairs, Tukey–Kramer test, p 
 0.05
for both comparisons; Fig. 8J; euIPSC amplitudes: 96.4 	 20.8
pA, n 5 pairs, Tukey–Kramer test, p
 0.05 for both compari-
sons). Data obtained by using the TRPV1 antagonist or the
TRPV1 knock-out mice to interfere with tonic 2-AG signaling
were highly similar (p 0.5 for both parameters).
Collectively, these findings provide direct evidence that highly
compartmentalized TRPV1 channels are concentrated on post-
synaptic intracellular membranes at hippocampal perisomatic,
but not at dendritic, GABAergic synapses. Moreover, the data
show that TRPV1 activation by endovanilloid signaling regulates
themagnitude of tonic 2-AG signaling at perisomatic GABAergic
synapses.
Discussion
The qualitative diversity and quantitative variability of synaptic
transmission are critically determined by neuromodulatory sig-
naling (Marder, 2012). PersistentCB1 receptor activity represents
one of the major modulatory mechanisms to establish synaptic
strength (Losonczy et al., 2004).Our present findings indicate the
following: (1) constitutively active CB1 receptors set GABA re-
lease probability selectively at perisomatic synapses in the hip-
pocampus; (2) 2-AG is the primary mediator of ligand-driven
tonic endocannabinoid signaling, but it is tightly controlled by
presynapticMGL activity; (3) amajor regulatorymechanism cal-
ibrating the homosynaptic 2-AG-mediated endocannabinoid
tone is endovanilloid signaling, which requires the activation of
TRPV1 channels predominantly located on postsynaptic intra-
cellular stores at GABAergic synapses; and (4) endovanilloid reg-
ulation of the 2-AG-mediated tone is controlled by FAAH.
Together, these findings demonstrate a striking spatial segrega-
tion and functional division of labor of distinct molecular com-
ponents of the endocannabinoid system in the tonic control of
neurotransmitter release.
Persistent CB1 activity at hippocampal GABAergic synapses
Although the mechanistic details and functional importance of
phasic endocannabinoid signaling have received widespread at-
tention (Cachope, 2012; Castillo et al., 2012), the molecular
mechanisms and significance of tonic endocannabinoid signaling
are much less understood. Tonic signaling represents a major
mode of operation for several other neuromodulatory systems,
with tonic adenosine and ambient GABA signaling being two
major examples (Brickley and Mody, 2012; Dias et al., 2013),
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suggesting that a deeper understanding of tonic cannabinoid
control on neurotransmitter release may also lead to important
insights. Therefore, our primary goal was to delineate how tonic
endocannabinoid signaling is organized at hippocampal GABAe-
rgic synapses. Because various physiological or pathophysiologi-
cal processes modulate endocannabinoid-mediated synaptic
plasticity (Iremonger et al., 2013; Melis et al., 2014), our second-
ary goal was to identify new regulatory mechanisms that can
fine-tune the extent of tonic endocannabinoid signaling at inhib-
itory synapses.
In the present study, the data revealed that AM251, an inverse
agonist of CB1 receptors, could readily increase GABAergic neu-
rotransmission. In contrast, NESS0327, a neutral antagonist, did
not have an effect on tonic cannabinoid signaling, although it
could block exogenous and endogenous ligand-activatedCB1 sig-
naling. This intriguing finding raises the possibility that a certain
proportion of the highly abundant CB1 receptors on perisomatic
boutons can take up a constitutively active conformation and
thereby persistently block nearby voltage-gated calcium channels
andGABA release (Szabo´ et al., 2014a). Indeed, biophysicalmod-
eling and mutational analysis identified several active conforma-
tions of CB1 receptors that trigger distinct downstream signaling
mechanisms with different kinetics and determine subcellular
receptor targeting (D’Antona et al., 2006; Simon et al., 2013;
Gyombolai et al., 2015). In light of previous evidence that CB1-
mediated inhibition of GABA release depends on the activity
pattern of the presynaptic neuron (Losonczy et al., 2004; Fo¨ldy et
al., 2006) together with the emerging therapeutic significance of
CB1 inverse agonism (Pertwee, 2005; Tam et al., 2012;Meye et al.,
2013), it will be pivotal to determine in the future the extent of
constitutive CB1 activity at other specific circuit locations and
during distinct physiological or pathophysiological states.
Tonic 2-AG signaling is controlled byMGL activity at
hippocampal GABAergic synapses
An alternativemechanism leading to persistent CB1 activity relies
on tonic endocannabinoid mobilization. Indeed, somatoden-
dritic CB1 receptors on hippocampal neurons are activated ton-
ically by 2-AG (Leterrier et al., 2006; Thibault et al., 2013; Ladarre
et al., 2014). Thus, although it is conceivable that the allosteric
conformational change induced by NESS0327 docking prevents
the extracellular 2-AG from reaching its intramembrane binding
pocket on CB1 receptors in the presynaptic membrane, the pos-
sibility that NESS0327 fails to displace prebound 2-AG also can-
not be fully excluded. Our finding that 2-AG is generated
tonically in acute slice preparations indicates that the latter sce-
nario is possible and has also general implication for synaptic
research performed in acute slice preparations because of the
widespread distribution of presynapticCB1 receptors throughout
the brain (Katona and Freund, 2012).
Our parallel lipid measurements and electrophysiological re-
cordings revealed that MGL activity limits 2-AG levels in the
hippocampus and controls how postsynapticallymobilized 2-AG
affects GABA release. In contrast, anandamide and FAAHdid not
have direct effects on GABAergic synapses. Generally, these find-
ings are consistent with the anatomical distribution of themolec-
ular constituents of the endocannabinoid system. FAAH is found
somatodendritically throughout the brain (Egertova´ et al., 1998;
Gulya´s et al., 2004); hence, it is segregated spatially from the
presynaptic effector site of tonic endocannabinoid signaling.
MGL is distributed ubiquitously within axon terminals, which is
the ideal subcellular position to terminate 2-AG effects at presyn-
aptic CB1 receptors (Gulya´s et al., 2004; Luda´nyi et al., 2008;
Uchigashima et al., 2011, Horva´th et al., 2014). Because down-
regulation of MGL levels is associated with various physiological
conditions and pathological situations (Sumislawski et al., 2011;
Kallendrusch et al., 2012; Serrano et al., 2012), our results also
highlight the importance to identify those mechanisms by which
the presynaptic neuron can adjust MGL activity.
Synapse specificity of tonic cannabinoid signaling
Our previous findings uncovered tonic endocannabinoid signal-
ing at perisomatic, but not dendritic, synaptic connections (Lee et
al., 2010). Present observations now extend these findings by
showing that neither tonic MGL nor tonic FAAH activity affects
GABAergic transmission, despite the presence of functionally ac-
tive CB1 receptors on dendritically projecting interneuron bou-
tons. One simple explanation is that cannabinoid signaling is
quantitatively different between perisomatic and dendritic axon
terminals because of the distinct nanoscale architecture of the
two terminals (Dudok et al., 2015). Indeed, we found that a CB1
receptor agonist more strongly inhibits GABA release from peri-
somatically projecting interneurons. An alternative explanation
could be the cell-type-specific expression of cannabinoid
receptor-interacting proteins, which bind to the C terminus of
CB1 and block constitutive receptor activity (Niehaus et al., 2007;
Smith et al., 2015).
The synapse specificity also provides clues as to why tonic
endocannabinoid signaling may sometimes appear absent,
when electrical stimulation of a heterogeneous mixture of fi-
ber types is used to evoke compound IPSCs (Pan et al., 2011).
Such a paradigm was shown to require the genetic inactivation
of MGL to uncover the presence of endocannabinoid tone
(Pan et al., 2011). Similarly, the absence of effect after FAAH
blockade does not exclude that anandamide conducts tonic
endocannabinoid signaling under specific physiological or
pathophysiological conditions, such as during chronic inhibi-
tion of neuronal firing (Kim and Alger, 2010). Considering
that postsynaptic neurons exploit tonic endocannabinoid sig-
naling in an activity- and cell-type-specific manner (Losonczy
et al., 2004; Hentges et al., 2005; Neu et al., 2007; Oliet et al.,
2007; Lee et al., 2010; Huang andWoolley, 2012), our findings
highlight the importance of focusing anatomical and physio-
logical analyses on identified circuit locations to elucidate how
cannabinoid signaling regulates circuit dynamics.
Synaptic division of labor between anandamide and 2-AG
signaling
A major unresolved subject of endocannabinoid research is
why the brain uses two different endocannabinoid substances
(Piomelli, 2014). Both anandamide and 2-AG are bona fide
CB1 ligands. Activation of presynaptic CB1 receptors inhibits
voltage-gated calcium channels, thereby reducing neurotrans-
mitter release (Twitchell et al., 1997; Sullivan, 1999; Hoffman
and Lupica, 2000). Interestingly, both endocannabinoids can
additionally activate TRPV1 channels (Zygmunt et al., 1999,
2013) and mediate long-term depression via postsynaptic
AMPA receptor internalization (Cha´vez et al., 2010; Grueter et
al., 2010; Puente et al., 2011).
Besides these independent synaptic functions of endocan-
nabinoid and endovanilloid signaling, we found that these two
pathways antagonistically interact to adjust synaptic strength at
hippocampal inhibitory synapses. Endovanilloid signaling was
reported to control 2-AG-mediated short-term plasticity evoked
by acute stimulation of mGlu5 glutamate receptors or M1 mus-
carinic acetylcholine receptors in the striatum (Maccarrone et al.,
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2008; Musella et al., 2010). The model proposed by Maccarrone
et al. (2008) also suggested that increased anandamide levels ac-
tivate TRPV1 channels, which then leads to an inhibition of the
2-AG-synthesizing enzyme DGL-. Consequently, mGlu5-
triggered increase in striatal 2-AG levels and phasic endocan-
nabinoid signaling were impaired after FAAH inhibition (Mac-
carrone et al., 2008). Our findings are entirely consistent with this
model by showing the following: (1) selective FAAH blockade
elevates anandamide levels but attenuates increased hippocampal
2-AG levels induced by MGL inhibition; (2) the latter effect is
associated with a weakened tonic 2-AG signaling; (3) reduced
2-AG signaling after FAAH blockade can be rescued by using a
potent TRPV1 antagonist or in TRPV1 knock-out mice; and (4)
TRPV1 is present postsynaptically at GABAergic synapses.
The mechanistic similarity of how endovanilloid signaling
controls endocannabinoid signaling in different brain areas sug-
gests that this functional interaction may be a more general phe-
nomenon than hitherto thought. Emerging evidence indicates
that TRPV1 activation has opposite behavioral function with re-
spect to CB1 signaling in several cognitive processes, including
hippocampus-dependent learning and anxiety (Marsch et al.,
2007; Li et al., 2008, Moreira et al., 2012; You et al., 2012). Im-
portantly, human FAAH variants that cause reduced enzyme ac-
tivity are also associatedwith decreased anxiety-related behaviors
and attenuated trauma in posttraumatic stress disorder patients
(Pardini et al., 2012; Dincheva et al., 2015). Thus, uncovering the
functional interaction of these two signaling systems in relation
to specific behavioral processes will also help to understand the
neurobiological mechanisms underlying the potential of FAAH
inhibitors as novel anxiolytics (Gunduz-Cinar et al., 2013).
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